Dasolampanel

Dasolampanel

Clinical data
ATC code	None
Identifiers
IUPAC name (3S,4aS,6S,8aR)-6-(3-Chloro-2-(1H-tetrazol-5-yl)phenoxy)decahydroisoquinoline-3-carboxylic acid
CAS Number	503294-13-1
PubChem CID	51049972
ChemSpider	25948207
UNII	1P85D6BE9K
KEGG	D10107
CompTox Dashboard (EPA)	DTXSID401032046
Chemical and physical data
Formula	C17H20ClN5O3
Molar mass	377.83 g·mol−1
3D model (JSmol)	Interactive image
SMILES c1cc(c(c(c1)Cl)c2[nH]nnn2)O[C@H]3CC[C@H]4CN[C@@H](C[C@H]4C3)C(=O)O
InChI InChI=1S/C17H20ClN5O3/c18-12-2-1-3-14(15(12)16-20-22-23-21-16)26-11-5-4-9-8-19-13(17(24)25)7-10(9)6-11/h1-3,9-11,13,19H,4-8H2,(H,24,25)(H,20,21,22,23)/t9-,10+,11-,13-/m0/s1 Key:LAKQPSQCICNZII-NOHGZBONSA-N

Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine. ^[1] It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection, ^{[2] [3]} but ultimately neither drug was ever marketed.

See also

• Irampanel
• Selurampanel

References

1. Stolerman IP (31 July 2010). Encyclopedia of Psychopharmacology. Springer Science & Business Media. pp. 514–. ISBN   978-3-540-68698-9.
2. Olesen J, Ramadan N (21 August 2008). Innovative Drug Development for Headache Disorders. Oxford University Press. pp. 188–. ISBN   978-0-19-955276-4.
3. Firestein GS, Budd R, Gabriel SE, O'Dell JR, McInnes IB (31 August 2012). Kelley's Textbook of Rheumatology: Expert Consult Premium Edition: Enhanced Online Features. Elsevier Health Sciences. pp. 1031–. ISBN   978-1-4557-3767-3.